My article Merck Ignores Molnupiravir’s Cytotoxicity is published in Trial Site News behind paywall. This is a free copy Molnupiravir-Cytotoxic-Merck.PDF.
The fraudulent and malicious marketing of Molnupiravir by Merck explains its campaign against Ivermectin. Its anti-Ivermectin statements should be considered part of its Molnupiravir marketing, and Merck should be held accountable. Continue reading Merck Ignores Molnupiravir Cytotoxicity
This article was first published by TrialSiteNews behind a paywall.
Merck’s Molnupiravir (also known as EIDD-2801 and MK-4482) is a mutagenic nucleotide analogue [1]. It introduces errors in the SARS-COV-2 RNA at the time of replication after proofreading, and causes lethal mutagenesis [2]. This threatens to accelerate the evolution of the coronavirus.
Any major variant of the coronavirus represents local optimum (in mutations space), maximizing coronavirus’ fitness. One- or two-point mutations cannot accomplish this. A new variant can only rise through the change of the virus-host-conditions systems, or through larger mutations set. Even a moderate increase in the point mutations frequency causes a big increase in the frequency of multi-point mutations and dangerous recombinations. Such events are too rare to be caught in small trials, but inevitable in large populations, and might lead to catastrophic consequences. The authorization and broad use of Molnupiravir is likely to breed very dangerous SARS-COV-2 variants. Continue reading Is Molnupiravir a Global Catastrophic Threat?
2021-10-04, preprint, self-published Cochrane-style
Leo Goldstein
Among the many vaccine technologies attempted for COVID-19 vaccines, the oldest technology – live unattenuated virus (LUV) vaccine – has hardly been mentioned. For the purposes of this article, a LUV vaccine refers to the process of administering a small amount of unattenuated virus in conjunction with the anti-viral against it [1]. Continue reading Live Unattenuated/Attenuated Virus Vaccines for COVID-19
2021-09-29: Some doctors under-dose Ivermectin by prescribing only 12 mg. This is not enough for the current variants! The current recommendations for early treatment is 0.5 mg/kg. That comes to 30-60 mg, depending on the patient’s weight. Ivermectin must be taken after a fatty meal.
Other components to choose from:
Nitazoxanide; and/or
HCQ + Zinc (Quercetin is an inferior substitution for HCQ); and/or
mouth rinsing / gargling / nasal irritation with Povidone-Iodine; and/or
Fluvoxamine or Doxycycline; and/or
Aspirin, Melatonin.
Vitamin C (3x 1,000 mg per day) and Vitamin D are always good.
The later stages require higher amount of Ivermectin
A Delta-specific version of COVID-19 vaccine has been developed months ago. Those who need a booster shot could have received it now. However, the FDA/CDC/NIH blocked its clinical trials and silenced even a discussion of it.
The current Delta strain (or serotype) of SARS-COV-2, now dominant in the US, is a far cry from the original Wuhan strain. All current vaccines target the original Wuhan strain. Both Moderna and Pfizer vaccines were developed and emergency authorized in 2020. The Delta strain is the result of the coronavirus evolving to evade limited immunity conferred by those vaccines.
The neutralizing effect of the antibodies elicited by the 2020 vaccines is 6-8x lower against the Delta than against the original Wuhan strain 1, 2. The higher replication rates of the Delta strain/serotype decrease vaccine effectiveness even further.
Thus, the original 2020 vaccines were not designed, and are not effective (except for few months as prophylaxis) against the current Delta strain / serotype. All the dangers and harms remain or become worse. Continue reading Suppression of the Delta-Specific Vaccine
2021-09-21, preprint, v.2.1, self-published Cochrane-style. Immunization-PVPI-v2.1.pdf
Medical Protocol Proposal
Leo Goldstein [1]
This theoretical article, building on the previous Protocol for Self Immunization against COVID-19 (Goldstein, 2021b), proposes cleaning the upper respiratory tract by gargling, mouth rinsing, and nasal irrigation (GMN) with PVP-I or common oral antiseptics as the infection stopping treatment. Such cleaning is intended to stop progression of a COVID-19 infection, after it has reached the minimum level necessary for immunity acquisition, and to constrain it to nasopharynx. GMN is already included in prophylaxis and/or early treatment of COVID-19 (FLCCC, 2021) , (Marik, 2021). The advantage of this proposed protocol is that the infection is interrupted early before symptoms appear. Continue reading Low Risk Natural Immunization against COVID-19
The Demented Puppet has signed a (putative) executive order, adding measles to the list of quarantinable diseases.
The quarantine laws allow all levels of governments to isolate, separate, and restrict movement of sick persons and those who were in their proximity. Except for COVID-19 and pandemic flu, this quarantinable diseases list only included very rare and dangerous infectious diseases such as Cholera, Diphtheria, Infectious Tuberculosis, Plague, Smallpox, Yellow fever, viral hemorrhagic fevers (Ebola and similar), severe acute respiratory syndromes (SARS, MERS). Each disease on the list is either highly lethal or epidemic, and most of them are both. Continue reading Why was Measles added to the list of quarantinable diseases?
As many have correctly noticed, the FDA has not approved any of the COVID-19 vaccines. All currently used Covid-19 vaccines are still under Emergency Use Authorization (EUA). So, the obvious questions are:
The FDA Approval Letter in the question is dated by August 23 and is signed by two directors of CBER offices. One of those directors is Marion Gruber, PhD, who has announced her future resignation, due to the CDC’s attempts to force an approval of a COVID-19 vaccine. Continue reading FDA Fiction — Fictional Approval of COVID-19 Vaccine
(Yahi et al., 2021) Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination? Continue reading Some papers about enhancing antibodies
All currently circulating strains of SARS-COV-2 (i.e., Delta sub-variants) have spike mutations L452R & T478K, disabling most vaccine induced antibodies. These strains also have aT19R mutation, disrupting epitopes in spike NTD. Many NTD-directed antibodies are known to cause ADE, especially when the epitopes which they target are disrupted.
These L452R/Q & T478K have been mutations of concern for many months. Pfizer & Moderna have had plenty of time to modify their vaccines and/or make a booster with the new spike mRNA. Surprisingly however, the Biden-Harris regime has not demanded any modifications to improve the vaccine to make it effective against the current SARS-COV-2 variants.
All the side effects and other harms remain.
2021-09-09, preprint, self-published Cochrane-style. TreatingEvolvingDelta-Zinc.PDF
Continue reading Medical hypothesis about the evolving Delta variant and its early treatment
2021-09-06: updated with the sub-variant AY.25. The situation is changing rapidly. This article is not being updated
The CDC uses W.H.O’s classification of the SARS-COV2 variants. W.H.O has failed to elevate Delta sub-variants into full variants when such a classification is more than warranted. Consequently, what has been called Delta (B.1.617.2) since May 2021 is a mix of many sub-variants with different properties. This confused clinicians and the CDC added to this confusion. Continue reading Delta Subvariants AY.3, AY.4, and A.25 are Dominant. The CDC Lies.